Gastroenteropancreatic Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors [Phase 2, Phase 3]
A Phase 2/3 clinical trial is evaluating sirolimus for injection (albumin-bound) in combination with octreotide long-acting injection in pat…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors [NA]
Clinical trial update for a dual tracer PET imaging study using 68Ga-DOTATATE and 18F-FDG in grade 2 and grade 3 gastroenteropancreatic neur…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Italian prospective observational study evaluating the effectiveness and outcomes of Lutathera treatment in patients with gastroenteropancre…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: DCEUS to Assess Treatment Response to PRRT in GEP-NET [NA]
This trial update discusses using dynamic contrast-enhanced ultrasound (DCEUS) to assess response to peptide receptor radionuclide therapy (…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE [Phase 3]
Phase 3 clinical trial comparing Lutetium-177Lu-Edotreotide to best standard of care in well-differentiated aggressive grade-2/grade-3 gastr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.